Agilent is a leader in life sciences, diagnostics and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications, and expertise, enabling customers to gain the insights they seek. Agilent is providing the entire workflow of target enrichment for different NGS applications such as cancer, infectious and rare diseases. including sample quality control (QC), next-generation sequencing (NGS) library prep and target enrichment, microarrays, CRISPR, PCR/qPCR, bioreagents, and data analysis solutions from interpretation reporting. Furthermore, with the extensive cancer diagnostic and pathology know-how of Agilent Dako, built on more than 50 years of experience, our business of antibodies & assay solutions has established lasting partnerships worldwide with partnering companies, ranging from large multinationals to smaller manufacturers and commercial laboratories specializing in the fields of in vitro diagnostics, biotechnology and pharmaceuticals. Besides the development of companion diagnostic for novel personalized therapy in cancer treatment, collaboration partners also benefit from the high level of familiarity of the Agilent Pathology-portfolio in routine diagnostic.
Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients previously diagnosed with cancer. Signatera's tumor-informed assay is optimized to detect low levels of ctDNA, with high accuracy in identifying MRD and recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers. The test is available for clinical and research use, and has been designated by the FDA as a Breakthrough Device. Look deeper at natera.com/oncology
We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.
With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
Owlstone Medical’s mission is to save 100,000 lives and $1.5 billion in healthcare costs by realizing the potential of breath biomarkers for early detection and precision medicine through Breath Biopsy®. Breath Biopsy provides reliable solutions for the collection and analysis of volatile organic compounds (VOCs) produced through metabolic processes or as a result of interaction with external factors such as diet or medication. Changes to exhaled VOCs can be associated with a range of disease conditions and environmental exposures.
NeoGenomics is an industry-leading cancer diagnostics and pharma services company. We enable advanced oncology patient care leveraging the most extensive diagnostic solid tumor and hematological test menus, sub-specialized pathology, and expertise in biomarker development. We partner closely with our pharma and research clients to meet program objectives and delivery from biomarker discovery through CDx validation and commercialization.
Sysmex America is lighting the way to better health with diagnostic solutions that transform the future of healthcare and contribute to healthier lives. Its innovative hematology, urinalysis and flow cytometry testing technology is reshaping the world of diagnostics across the U.S., Canada and Latin America. As a trusted global leader, Sysmex offers diagnostics that equip patients and the health care professionals who treat them with the information needed to make decisions with confidence.
PHC Holdings Corporation is a global healthcare company with its products and services used in more than 125 countries. Subsidiaries include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia and LSI Medience Corporation. The company develops, manufactures, sells and services medical equipment and solutions across the diabetes management, diagnostics, life sciences and healthcare services. Epredia is a global leader in the anatomical pathology field, providing comprehensive solutions for precision cancer diagnostics. URL: www.phchd.com
Predicine is a molecular insights company committed to advancing biomarker-driven precision medicine. It has developed a breakthrough cell-free DNA and cell-free RNA based liquid biopsy technology for non-invasive cancer profiling, disease monitoring, assessing MRD, and early cancer detection. Predicine partners with leading biopharma companies and hospitals to support global clinical trials and personalized cancer care.
Arima Genomics is a biotechnology company that advances the life sciences through the power of 3D genomes. We develop innovative solutions that drive discovery in genomics and improve human health. Our advanced Hi-C technology enables a range of products and applications by providing unparalleled access to the sequence and structure of any genome.